Patents by Inventor Alistair Vincent Gordon EDWARDS

Alistair Vincent Gordon EDWARDS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210244798
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: April 6, 2020
    Publication date: August 12, 2021
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Patent number: 10905745
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: February 2, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Bjarne Due Larsen, Jonathan Griffin, Lise Giehm, Alistair Vincent Gordon Edwards
  • Publication number: 20200297818
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: April 6, 2020
    Publication date: September 24, 2020
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Publication number: 20190365865
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: August 19, 2019
    Publication date: December 5, 2019
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Publication number: 20190338009
    Abstract: The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: December 11, 2017
    Publication date: November 7, 2019
    Inventors: Bjarne Due LARSEN, Lise GIEHM, Alistair Vincent Gordon EDWARDS
  • Publication number: 20190142904
    Abstract: A compound having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, and a pharmaceutical composition containing the compound or a pharmaceutically acceptable salt or solvate thereof in admixture with a pharmaceutically acceptable carrier, an excipient or a vehicle are provided. The compound can be used, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis or treatment of metabolic dysfunction.
    Type: Application
    Filed: November 19, 2018
    Publication date: May 16, 2019
    Inventors: Bjarne DUE LARSEN, Jonathan GRIFFIN, Lise GIEHM, Alistair Vincent Gordon EDWARDS